Media stories about Novartis (NYSE:NVS) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.9805131217458 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Form SC TO-T AveXis, Inc. Filed by: NOVARTIS AG (streetinsider.com)
- Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab … (globenewswire.com)
- Expectations from Novartis’s 1Q18 Earnings (marketrealist.com)
- Switzerland’s Novartis to inject $100 million into malaria drug research (thelocal.ch)
- Blockbuster ambitions: Amgen/Novartis team lines up more promising PhIII erenumab data for some of the toughest … (endpts.com)
NVS has been the topic of several analyst reports. Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Wednesday, December 27th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. UBS reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. JPMorgan Chase reissued a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. Finally, Deutsche Bank reissued a “neutral” rating on shares of Novartis in a report on Tuesday, April 10th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and an average target price of $87.51.
Novartis (NYSE:NVS) last posted its earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The business had revenue of $12.92 billion for the quarter, compared to analyst estimates of $12.65 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. sell-side analysts anticipate that Novartis will post 5.3 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Novartis (NVS) Receives Media Impact Rating of 0.19” was originally posted by Week Herald and is owned by of Week Herald. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://weekherald.com/2018/04/17/novartis-nvs-receives-media-impact-rating-of-0-19.html.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.